Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies (VERANDA™-IIM)

14 september 2026 bijgewerkt door: Boehringer Ingelheim

A Phase III, Parallel Design, Double-blind, Randomised, Placebo-controlled, Multi-centre Trial to Evaluate the Efficacy and Safety of Nerandomilast Oral Therapy Added to Standard Background Therapy Over 52 Weeks in Adult Trial Participants With Active Idiopathic Inflammatory Myopathies (VERANDA™-IIM)

This study is open to adults aged 18 and older who have a condition known as active idiopathic inflammatory myopathy (IIM) or myositis. People can participate if they have a specific type of myositis. The purpose of this study is to find out whether a medicine called nerandomilast improves IIM symptoms.

Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take nerandomilast or placebo twice a day for 1 year.

Participants are in the study for about 1 year and 2 months. During this time, they visit the study site at least 16 times. During this time, doctors regularly check the participant's health, IIM symptoms, and take note of any unwanted effects. Participants fill in questionnaires about their IIM symptoms and how IIM impacts their quality of life. The results are compared between the 2 groups to see whether the treatment works.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

270

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

  • Argentinië
      • C.a.b.a, Argentinië, C1426BOD
      • CABA, Argentinië, C1405BFN
      • CABA, Argentinië, C1113
        • Centro Argentino de Investigacion (CADI)-Diagnostico Medico
        • Contact:
      • Capital Federal, Argentinië, C1405BCH
      • La Plata, Argentinië, B1902COS
      • Quilmes, Argentinië, B1878DVB
      • Rosario, Argentinië, S2000ORE
      • San Miguel de Tucumán, Argentinië, 4000
      • Villa Nueva, Argentinië, M5526DRW
  • Australië
    • New South Wales
      • Wollongong, New South Wales, Australië, 2500
    • Victoria
      • Ivanhoe, Victoria, Australië, 3079
  • België
      • Ghent, België, 9000
      • Jette, België, 1090
      • Leuven, België, 3000
      • Liège, België, 4000
        • Centre Hospitalier Universitaire de Liege
        • Contact:
  • Brazilië
      • Juiz de Fora, Brazilië, 36010-570
        • Centro Mineiro de Pesquisa (CMIP)
        • Contact:
      • Porto Alegre - RS, Brazilië, CEP 90020-090
        • Irmandade da Santa Casa de Misericórdia de Porto Alegre
        • Contact:
      • Salvador, Brazilië, 40221-500
      • São Paulo, Brazilië, 01246-903
        • Hospital Das Clinicas Da Faculdade De Medicina Da USP
        • Contact:
      • Valinhos, Brazilië, 13271-130
        • Azidus Centro de Pesquisa Clinica Avancada
        • Contact:
  • Bulgarije
      • Haskovo, Bulgarije, 6304
      • Sofia, Bulgarije, 1431
      • Sofia, Bulgarije, 1612
        • University Multiprofile Hospital for Active Treatment St. Ivan Rilski EAD
        • Contact:
  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2N 4Z6
    • Quebec
      • Sherbrooke, Quebec, Canada, J1E 0N8
        • Diex Recherche (Sherbrooke Est)
        • Contact:
  • China
      • Beijing, China, 100730
        • Peking Union Medical College Hospital
        • Contact:
      • Beijing, China, 100029
        • China-Japan Friendship Hospital
        • Contact:
      • Chongqing, China, 400010
        • Second Affiliated Hospital Chongqing Medical University
        • Contact:
      • Dongguan, China, 523059
      • Guangzhou, China, 510080
        • Guangdong Provincial People's Hospital
        • Contact:
      • Guangzhou, China, 510630
        • The third affiliated hospital of Sun Yat-Sen University
        • Contact:
      • Hefei, China, 230001
      • Luoyang, China, 471003
        • The First Affiliated Hospital of Henan University of Science and Technology
        • Contact:
      • Nanchang, China, 330038
        • The Second Affiliated Hospital to Nanchang University
        • Contact:
      • Nanjing, China, 210008
      • Shanghai, China, 200040
        • Huashan Hospital, Fudan University
        • Contact:
      • Shanghai, China, 200025
        • Ruijin Hospital Shanghai Jiao Tong University School of Medicine
        • Contact:
      • Shanghai, China, 201112
        • Renji Hospital Shanghai Jiaotong University School of Medicine
        • Contact:
      • Wenzhou, China, 325000
        • The First Affiliated Hospital of Wenzhou Medical University
        • Contact:
      • Wuhan, China, 430030
        • Tongji Hospital Affiliated Tongji Medical College Huazhong University of S & T
        • Contact:
      • Xi'an, China, 710061
        • First Affiliated Hospital of Xi'an JiaoTong University
        • Contact:
  • Duitsland
      • Bad Bramstedt, Duitsland, 24576
      • Berlin, Duitsland, 13125
      • Cologne, Duitsland, 51149
      • Erlangen, Duitsland, 91054
      • Freiburg im Breisgau, Duitsland, 79106
      • Halle, Duitsland, 06120
      • Jena, Duitsland, 07747
      • Kirchheim unter Teck, Duitsland, 73230
      • Tübingen, Duitsland, 72076
      • Ulm, Duitsland, 89081
      • Würzburg, Duitsland, 97080
  • Frankrijk
      • Angers, Frankrijk, 49933
      • Bordeaux, Frankrijk, 33076
      • Caen, Frankrijk, 14000
      • Lyon, Frankrijk, 69437
      • Paris, Frankrijk, 75010
      • Paris, Frankrijk, 75013
        • Hôpital de la Pitié Salpêtrière
        • Contact:
      • Strasbourg, Frankrijk, 67091
      • Toulouse, Frankrijk, 31059
        • Hôpital Rangueil - CHU de Toulouse
        • Contact:
  • Griekenland
      • Thessaloniki, Griekenland, 546 42
        • General Hospital of Thessaloniki "Ippokrateio"
        • Contact:
  • Hongarije
  • Italië
      • Bari, Italië, 70124
        • Azienda Universitaria Ospedaliera Consorziale Policlinico Bari
        • Contact:
      • Catania, Italië, 95121
        • Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania
        • Contact:
      • Padova, Italië, 35100
      • Pavia, Italië, 27100
        • Fondazione IRCCS Policlinico S. Matteo
        • Contact:
      • Pisa, Italië, 56126
        • Azienda Ospedaliera Universitaria Pisana
        • Contact:
      • Torino, Italië, 10126
        • Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino
        • Contact:
  • Japan
      • Aichi, Nagoya, Japan, 457-8510
        • Japan Community Healthcare Organization Chukyo Hospital
        • Contact:
      • Fukuoka, Kitakyushu, Japan, 807-8556
        • Hospital of the University of Occupational and Environmental Health
        • Contact:
      • Fukushima, Fukushima, Japan, 960-1295
        • Fukushima Medical University Hospital
        • Contact:
      • Hokkaido, Sapporo, Japan, 060-8648
      • Kanagawa, Kawasaki, Japan, 216-8511
        • St. Marianna University Hospital
        • Contact:
      • Kanagawa, Yokohama, Japan, 236-0004
        • Yokohama City University Hospital
        • Contact:
      • Kyoto, Kyoto, Japan, 606-8507
      • Miyagi, Sendai, Japan, 983-8512
        • Tohoku Medical and Pharmaceutical University Hospital
        • Contact:
      • Nara, Kashihara, Japan, 634-8522
        • Nara Medical University Hospital
        • Contact:
      • Okayama, Okayama, Japan, 700-8558
      • Osaka, Suita, Japan, 565-0871
        • The University of Osaka Hospital
        • Contact:
      • Tokyo, Bunkyo-ku, Japan, 113-8431
      • Tokyo, Bunkyo-ku, Japan, 113-8603
      • Tokyo, Bunkyo-ku, Japan, 113-8519
        • Institute of Science Tokyo Hospital
        • Contact:
      • Tokyo, Ota-ku, Japan, 143-8541
        • Toho University Omori Medical Center
        • Contact:
      • Tokyo, Shinjuku-ku, Japan, 160-0023
        • Tokyo Medical University Hospital
        • Contact:
      • Tokyo, Shinjuku-ku, Japan, 162-8666
        • Tokyo Women's Medical University Hospital
        • Contact:
      • Tokyo, Shinjuku-ku, Japan, 160-8582
  • Mexico
      • Chihuahua City, Mexico, 31203
        • Mediadvance Clinical S.A.P.I de C.V.
        • Contact:
      • Guadalajara, Mexico, 44670
        • Panamerican Clinical Research Mexico
        • Contact:
      • Guadalajara, Mexico, 44160
        • Centro Integral en Reumatologia, SA. de CV.
        • Contact:
      • León, Mexico, 37000
      • Mexico City, Mexico, 14080
        • Inst Nac de Ciencias Medicas y Nutricion Salvador Zubiran
        • Contact:
      • Mexico City, Mexico, 06700
        • CITER Centro de Investigación y Tratamiento de las Enfermedades Reumaticas SA de CV
        • Contact:
      • Mérida, Mexico, 97070
        • Medical Care & Research SA de CV
        • Contact:
  • Nederland
      • Amsterdam, Nederland, 1105 AZ
  • Polen
      • Bialystok, Polen, 15-707
        • Nova Reuma Domyslawska I Rusilowicz - Spolka Partnerska Lekarza Reumatologa I Fizjoterapeuty
        • Contact:
      • Bydgoszcz, Polen, 85-168
        • Szpital Uniwersytecki Nr 2 Im Dr Jana Biziela W Bydgoszczy
        • Contact:
      • Katowice, Polen, 40635
        • Gornoslaskie Centrum Medyczne im prof. Leszka Gieca Slaskiego Uniwersytetu Medycznego W Katowicach
        • Contact:
  • Portugal
      • Aveiro, Portugal, 3814-501
      • Coimbra, Portugal, 3004-561
        • CHUC - Centro Hospitalar e Universitario de Coimbra, EPE
        • Contact:
      • Lisbon, Portugal, 1649-035
  • Roemenië
      • Bucharest, Roemenië, 020475
      • Bucharest, Roemenië, 020983
        • Centrul Clinic De Boli Reumatismale Dr. Ion Stoia
        • Contact:
      • Cluj-Napoca, Roemenië, 400006
        • Spitalul Clinic Judetean de urgenta Cluj
        • Contact:
  • Servië
      • Belgrade, Servië, 11000
      • Belgrade, Servië, 11040
      • Kragujevac, Servië, 34000
        • University Clinical Center of Kragujevac
        • Contact:
  • Spanje
      • Barcelona, Spanje, 08036
      • Barcelona, Spanje, 08035
        • Hospital Universitari Vall d'Hebron
        • Contact:
      • Barcelona, Spanje, 08041
      • Madrid, Spanje, 28041
        • Hospital Universitario 12 de Octubre
        • Contact:
      • Madrid, Spanje, 28006
        • Hospital Universitario de La Princesa
        • Contact:
      • Málaga, Spanje, 29010
        • Hospital Universitario Virgen de la Victoria
        • Contact:
      • Valencia, Spanje, 46017
  • Taiwan
      • Kaohsiung City, Taiwan, 80756
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
        • Contact:
      • Taichung, Taiwan, 40705
        • Taichung Veterans General Hospital
        • Contact:
      • Taichung, Taiwan, 402
        • Chung Shan Medical University Hospital
        • Contact:
      • Taipei, Taiwan, 11217
        • Taipei Veterans General Hospital
        • Contact:
  • Thailand
      • Bangkok, Thailand, 10700
      • Chiang Mai, Thailand, 50200
        • Maharaj Nakom Chiangmai Hospital
        • Contact:
      • Hat Yai, Thailand, 90110
        • Songklanagarind Hospital
        • Contact:
      • Ratchathewi, Thailand, 10400
  • Verenigde Staten
    • Arizona
      • Phoenix, Arizona, Verenigde Staten, 85028
      • Scottsdale, Arizona, Verenigde Staten, 85259
    • California
      • Irvine, California, Verenigde Staten, 92697
      • Los Angeles, California, Verenigde Staten, 90095
      • San Francisco, California, Verenigde Staten, 94115
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80045
    • Florida
      • Orlando, Florida, Verenigde Staten, 32819
    • Kansas
      • Fairway, Kansas, Verenigde Staten, 66205
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21224
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02115
    • Michigan
      • Ann Arbor, Michigan, Verenigde Staten, 48109-5314
    • Minnesota
      • Rochester, Minnesota, Verenigde Staten, 55905
    • Missouri
      • St Louis, Missouri, Verenigde Staten, 63110
    • New York
      • Great Neck, New York, Verenigde Staten, 11021
    • Ohio
      • Cleveland, Ohio, Verenigde Staten, 44195
      • Middleburg Heights, Ohio, Verenigde Staten, 44130
    • Oregon
      • Portland, Oregon, Verenigde Staten, 97239
    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 19104
    • Tennessee
      • Jackson, Tennessee, Verenigde Staten, 38305
    • Texas
      • Dallas, Texas, Verenigde Staten, 75231
      • Houston, Texas, Verenigde Staten, 77030
  • Zuid -Korea
      • Gwangju, Zuid -Korea, 61469
        • Chonnam National University Hospital
        • Contact:
      • Seoul, Zuid -Korea, 03080
        • Seoul National University Hospital
        • Contact:
      • Seoul, Zuid -Korea, 02447
      • Seoul, Zuid -Korea, 04763
        • Hanyang University Medical Center
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion criteria:

  1. Male or female adult individuals from ≥18 years of age (or alternative age for adults based on local regulations) on the date of signing the informed consent.
  2. A definite or probable clinical diagnosis of idiopathic inflammatory myopathy (IIM) according to the 2017 American college of rheumatology (ACR)/European alliance of associations of rheumatology (EULAR) classification criteria.
  3. Participants with overlap myositis (OM) must have IIM as the predominant disease.
  4. Participants ≥18 years of age (or alternative age for adults based on local regulations) with juvenile dermatomyositis (JDM) can only be included if they were 15 years old or older at first onset of DM symptoms.
  5. Disease activity defined by moderate to severe myopathy.
  6. The participant must be on background therapy for IIM.
  7. Woman (or women) of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control for a period of 28 days before treatment initiation, throughout the trial, and for a period of at least 5 days after the last dose of investigational medicinal product (IMP). WOCBP taking oral contraceptives also have to use one barrier method.
  8. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial. 9. Further inclusion criteria apply.

Exclusion criteria:

  1. Major surgery (major according to the investigator's assessment, e.g. hip replacement) performed within 6 weeks prior to randomisation or planned during the trial period.
  2. Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin, or in situ squamous cell carcinoma of the skin, or in situ carcinoma of uterine cervix.
  3. Participants who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
  4. Participants diagnosed with advanced interstitial lung disease (ILD).
  5. Severe muscle damage.
  6. Further exclusion criteria apply.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Nerandomilast
Geneesmiddel: Nerandomilast
Nerandomilast
Placebo-vergelijker: Placebo
Placebo matching nerandomilast
Geneesmiddel: Placebo
Placebo-matching nerandomilast

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Total improvement score (TIS) score (continuous) at Week 52
Tijdsspanne: At Week 52.
The TIS composite score includes 6 core set measures: manual muscle testing (MMT8), extra-muscular disease activity (MDAAT), patient global disease activity (PtGA), physician global disease activity (PhGA), health assessment questionnaire disability index (HAQ-DI), and muscle enzymes. An improvement score for each core set measure will be assigned using the absolute percent change, based on predetermined ranges. The TIS will be the sum of the all core set measure, scoring from 0 to 100, with higher scores corresponding to a greater degree of improvement.
At Week 52.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Achievement of a TIS-40 response (yes/no; defined as TIS ≥40) at Week 52
Tijdsspanne: At Week 52.
Number of participants with 40 TIS points or higher.
At Week 52.
Achievement of a successful tapering of oral corticosteroids (OCS) (yes/no) at Week 52
Tijdsspanne: At Week 52.
Number of participants achieving a TIS-40 response at Week 52 and ≤5 mg/day of prednisone (or equivalent) at Week 52
At Week 52.
Change from baseline in cutaneous dermatomyositis disease area and severity index activity score (CDASI-A) at Week 52 (in participants with baseline CDASI-A ≥6)
Tijdsspanne: At baseline and at Week 52.
The Cutaneous Dermatomyositis Disease Area and Severity Index activity score (CDASI-A) is a questionnaire assessing skin disease activity and damage in patients with dermatomyositis (DM). It ranges from 0 to 100, with higher values indicating more severe active skin involvement.
At baseline and at Week 52.
Change from baseline in extra-muscular disease activity as per myositis disease activity assessment tool (MDAAT) at Week 52
Tijdsspanne: At baseline and at Week 52.
Myositis Disease Activity Assessment Tool (MDAAT) is a questionnaire assessing the disease activity of extra-muscular organ systems and muscle in participants with IIM. It is a combined tool with two parallel scores: the MYOACT VAS and the MITAX. The Myositis disease activity assessment (MYOACT) visual analogue scale (VAS) scores the overall severity of disease activity. The sum of the individual scores ranges from 0 to 70, The higher the more severe. For the Myositis Intention-to-Treat Activity Index (MITAX), each question is answered with either: 0 = not present; 1 = improving; 2 = the same; 3 = worse; 4 = new. The summed scores are summed to obtain a total MITAX score with a range of 0 to 63, the higher the more severe.
At baseline and at Week 52.
Change from baseline in PtGA at Week 52
Tijdsspanne: At baseline and at Week 52.
Patient global disease activity (PtGA) measures the participant's self-assessment of the disease. It is composed of a 100 mm visual analogue scale. Patients will mark their assessment between "extremely poor" (0) and "excellent" (100). The difference between 0 (extremely poor) and the patient assessment is the PtGA, where higher distances indicate a better health status.
At baseline and at Week 52.
Change from baseline in PhGA at Week 52
Tijdsspanne: At baseline and at Week 52.
Physician global activity (PhGA) captures the physician's assessment of the participant's overall health. It is composed of a 100 mm visual analogue scale. Physicians will mark their assessment between "extremely poor" (0) and "excellent" (100). The difference between 0 (extremely poor) and the physician assessment is the PhGA, where higher distances indicate a better health status.
At baseline and at Week 52.
Change from baseline in HAQ-DI at Week 52
Tijdsspanne: At baseline and at Week 52.
The health assessment questionnaire disability index (HAQ-DI) assesses difficulties in performing activities of daily living across 8 domains. Each domain is rated on a scale of 0-3. The higher the score, the higher the disability.
At baseline and at Week 52.
Change from baseline in MMT-8 score at Week 52
Tijdsspanne: At baseline and at Week 52.
Manual Muscle Testing (MMT-8) assesses the muscle strength of 8 proximal, distal, and axial muscle groups. Each item is rated from 0 to 10, with the total score ranging from 0 to 150, where higher scores mean better muscle strength condition.
At baseline and at Week 52.
Achievement of a TIS-60 response (yes/no; defined as TIS ≥60) at Week 52
Tijdsspanne: At baseline and at Week 52.
At baseline and at Week 52.
Change from baseline in the most abnormal baseline muscle enzymes (aldolase, CK, AST, ALT, or LDH) at Week 52
Tijdsspanne: At baseline and at Week 52.
CK means creatine kinase, AST means aspartate aminotransferase, ALT means alanine aminotransferase, and LDH means lactate dehydrogenase.
At baseline and at Week 52.
Change from baseline in clinical-reported outcome 1 at Week 12
Tijdsspanne: At baseline and at Week 12.
At baseline and at Week 12.
Change from baseline in clinical-reported outcome 2 at Week 12
Tijdsspanne: At baseline and at Week 12.
At baseline and at Week 12.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Boehringer Ingelheim

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Nuttige links

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

9 november 2026

Primaire voltooiing (Geschat)

21 maart 2030

Studie voltooiing (Geschat)

26 maart 2030

Studieregistratiedata

Eerst ingediend

24 augustus 2026

Eerst ingediend dat voldeed aan de QC-criteria

24 augustus 2026

Eerst geplaatst (Werkelijk)

27 augustus 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 september 2026

Laatste update ingediend die voldeed aan QC-criteria

14 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 1305-0146
  • U1111-1338-2454 (Register-ID: WHO International Clinical Trials Registry Platform (ICTRP))
  • 2026-526365-24-00 (Register-ID: CTIS)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

IPD-tijdsbestek voor delen

One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

IPD-toegangscriteria voor delen

For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren